Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes

INTRODUCTION Alzheimer's Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE‐1 inhibitor umibecestat in cognitively unimpaired 60‐ to 75‐year‐old participants at genetic risk for Alzheimer's disease (AD). The study was reduced...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alzheimer's & dementia 2024-03, Vol.20 (3), p.1839-1850
Hauptverfasser:	Riviere, Marie‐Emmanuelle, Langbaum, Jessica B., Turner, R. Scott, Rinne, Juha O., Sui, Yihan, Cazorla, Pilar, Ricart, Javier, Meneses, Kathleen, Caputo, Angelika, Tariot, Pierre N., Reiman, Eric M., Graf, Ana
Format:	Artikel
Sprache:	eng
Schlagworte:	Accumulation active immunotherapy Age of onset Alzheimer's disease amyloid apolipoprotein E genotype Apolipoproteins Biomarkers Brain research CAD106 cognitively unimpaired Dementia Disease prevention Genetic susceptibility Health risk assessment Immunoglobulins Immunotherapy Medical research Monoclonal antibodies Positron emission tomography preclinical Prevention Proteins Serum Termination Tomography vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!